The recent, increasing amount of knowledge regarding lung cancer, especially in the field of basic science, holds promise for personalized treatment of these patients that would provide more effective and less toxic therapeutic approaches, improving the prognosis of the patients with thoracic malignancies. On the other hand, the immense bulk and the rapid recycling of the new information makes difficult its understanding, evaluation and interpretation by the clinicians. Therefore, the \u00abtranslation\u00bb of our recently acquired knowledge from the lab bench to the bedside is neither smooth nor is it without obstructions, due to the existing \u00abgaps\u00bb in our understanding and the often contradictory \u00absignals\u00bb from clinical trials.
\nThe success of our six previous meetings has prompted us to organize the 7th Lung Cancer Network \u00abFrom the Bench to the Bedside\u00bb. Our aim is to narrow the distance between the bench lab and the patient\u2019s bed, between the clinical trials outcome and the routine practice, by bringing together basic scientists, clinical researchers and lung cancer specialists. Our multidisciplinary, international faculty will present the latest clinical data and provide treating physicians with practical information regarding the clinical significance of the histological, molecular and genetic profile of the tumor and how the implementation of targeted agents in the therapeutic algorithm changes the clinical practice of lung cancer patients.<\/p>\n
<\/p>\n
\u0394\u03b5\u03af\u03c4\u03b5 \u03c4\u03bf \u03c0\u03c1\u03cc\u03b3\u03c1\u03b1\u03bc\u03bc\u03b1 \u03b5\u03b4\u03ce<\/p>\n
2020<\/a><\/p>\n 2018<\/a><\/p>\n